Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians
- PMID: 25928075
- DOI: 10.7326/M14-2426
Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians
Abstract
Description: The purpose of this best practice advice article is to describe the indications for screening for cervical cancer in asymptomatic, average-risk women aged 21 years or older.
Methods: The evidence reviewed in this work is a distillation of relevant publications (including systematic reviews) used to support current guidelines.
Best practice advice 1: Clinicians should not screen average-risk women younger than 21 years for cervical cancer.
Best practice advice 2: Clinicians should start screening average-risk women for cervical cancer at age 21 years once every 3 years with cytology (cytologic tests without human papillomavirus [HPV] tests).
Best practice advice 3: Clinicians should not screen average-risk women for cervical cancer with cytology more often than once every 3 years.
Best practice advice 4: Clinicians may use a combination of cytology and HPV testing once every 5 years in average-risk women aged 30 years or older who prefer screening less often than every 3 years.
Best practice advice 5: Clinicians should not perform HPV testing in average-risk women younger than 30 years.
Best practice advice 6: Clinicians should stop screening average-risk women older than 65 years for cervical cancer if they have had 3 consecutive negative cytology results or 2 consecutive negative cytology plus HPV test results within 10 years, with the most recent test performed within 5 years.
Best practice advice 7: Clinicians should not screen average-risk women of any age for cervical cancer if they have had a hysterectomy with removal of the cervix.
Comment in
-
Celebrating the ACP Centennial: From the Annals Archive--Cervical Cancer Screening.Ann Intern Med. 2015 Jun 16;162(12):868. doi: 10.7326/M15-0760. Ann Intern Med. 2015. PMID: 26075758 No abstract available.
Summary for patients in
-
Summaries for Patients. Cervical Cancer Screening in Average-Risk Women.Ann Intern Med. 2015 Jun 16;162(12):I-28. doi: 10.7326/P15-9019. Ann Intern Med. 2015. PMID: 25928137 No abstract available.
Similar articles
-
Summaries for Patients. Cervical Cancer Screening in Average-Risk Women.Ann Intern Med. 2015 Jun 16;162(12):I-28. doi: 10.7326/P15-9019. Ann Intern Med. 2015. PMID: 25928137 No abstract available.
-
Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2012 Jun 19;156(12):880-91, W312. doi: 10.7326/0003-4819-156-12-201206190-00424. Ann Intern Med. 2012. PMID: 22711081
-
The Korean guideline for cervical cancer screening.J Gynecol Oncol. 2015 Jul;26(3):232-9. doi: 10.3802/jgo.2015.26.3.232. J Gynecol Oncol. 2015. PMID: 26197860 Free PMC article.
-
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Vaccine. 2012. PMID: 23199969 Review.
-
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.Obstet Gynecol. 2004 Feb;103(2):304-9. doi: 10.1097/01.AOG.0000109426.82624.f8. Obstet Gynecol. 2004. PMID: 14754700 Review.
Cited by
-
Patient Perceptions on the Follow-Up of Abnormal Cancer Screening Test Results.J Gen Intern Med. 2024 Oct 18. doi: 10.1007/s11606-024-09128-4. Online ahead of print. J Gen Intern Med. 2024. PMID: 39424768
-
Surgical Treatment for Early Cervical Cancer in the HPV Era: State of the Art.Healthcare (Basel). 2023 Nov 10;11(22):2942. doi: 10.3390/healthcare11222942. Healthcare (Basel). 2023. PMID: 37998434 Free PMC article. Review.
-
A Multilevel Primary Care Intervention to Improve Follow-Up of Overdue Abnormal Cancer Screening Test Results: A Cluster Randomized Clinical Trial.JAMA. 2023 Oct 10;330(14):1348-1358. doi: 10.1001/jama.2023.18755. JAMA. 2023. PMID: 37815566 Free PMC article. Clinical Trial.
-
The Influence of Vaginal HPV Self-Sampling on the Efficacy of Populational Screening for Cervical Cancer-An Umbrella Review.Cancers (Basel). 2022 Nov 30;14(23):5913. doi: 10.3390/cancers14235913. Cancers (Basel). 2022. PMID: 36497396 Free PMC article. Review.
-
Primary Care Practitioner Perceptions on the Follow-up of Abnormal Cancer Screening Test Results.JAMA Netw Open. 2022 Sep 1;5(9):e2234194. doi: 10.1001/jamanetworkopen.2022.34194. JAMA Netw Open. 2022. PMID: 36173627 Free PMC article. Clinical Trial.